{"id":"NCT00597428","sponsor":"Sucampo Pharma Americas, LLC","briefTitle":"Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone","officialTitle":"A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2008-01-18","resultsPosted":"2015-12-07","lastUpdate":"2019-12-10"},"enrollment":437,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Opioid-Induced Bowel Dysfunction"],"interventions":[{"type":"DRUG","name":"Lubiprostone","otherNames":["AmitizaÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":["No other names"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Lubiprostone","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with opioid-induced bowel dysfunction (OBD).","primaryOutcome":{"measure":"Change From Baseline in Mean Weekly Spontaneous Bowel Movement (SBM) Frequency in Subjects Without Dose Reduction Prior to Week 8","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"Placebo","deltaMin":2.4,"sd":3.2},{"arm":"Lubiprostone","deltaMin":2.6,"sd":3.26}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":114,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":214},"commonTop":["Nausea","Diarrhoea","Flatulence","Vomiting"]}}